Biosimilars, Biobetters and Captain America: The Future of Biosimilars in a World of Biobetters

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Research Analyst

After being untouchable for decades, US biologics companies are finally facing biosimilar competition.  Well, sort of.  Cutting Edge Information’s report on counter-generics strategies found that the high cost of biosimilar production will not allow companies to price biosimilars substantially below that of the original product – meaning they may not have the same market impact that a typical generic would.  Instead, biobetters may be the next biggest thing to rock the biologics world. Continue reading




Protecting Profitability: Translating Strong Health Economics and Outcomes Research to Drive Interactions with Medical Device Payers and More

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Health economics and outcomes research (HEOR) groups have carved out their place in life sciences organizations throughout the industry. Though pharmaceutical and biotech companies have long-since accepted the utility of this function, many medical device companies have leveraged other groups to perform HEOR tasks — often ad hoc. Now, HEORs prominence is more widespread, and device companies are structuring health economics staff to take on a number of reimbursement-related responsibilities. One of these teams most prominent activities is aiding interactions with government and private medical device payers. Continue reading



Patient-Reported Outcomes Spurred by Big Data in Pharma

The opportunities are countless for Big Data in pharma, particularly within the clinical trial space.  Harnessing the data generated during clinical trials could help shorten trial timelines and lead to less expensive and more efficient drug discovery and development.  In a recent report, Pharmaceutical Big Data Insights, we examined some of the applications of Big Data in these prospective trials and how companies are wrangling all the information into usable insights.  Surveyed companies conducting prospective studies report which data they use most: topping the list at 80% is health outcomes data, followed by patient-reported outcomes (PROs) and clinical trial data (see Figure 1). Continue reading



HEORs and Tails: Why Is Staffing Market Access Teams So Difficult?

Pharmaceutical market access teams hold a wide range of responsibilities and, as such, require employees with a variety of knowledge and skills.  Organizations that create a well-rounded market access team can work with payers better to achieve an optimal reimbursement amount and stay competitive in the marketplace.  Finding these employees is much easier said than done, however.  Half of companies surveyed for a new report ranked finding skilled employees as either challenging or very challenging (Figure 1).  Pharmaceutical market access groups have only one primary goal (among a number of secondary goals): to achieve reimbursement.  Why do the people for this job need to be so multi-talented?  Continue reading


Product Pricing in Emerging Markets

In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics and regulatory reforms.

To address these challenges, many companies are turning to integrated teams that include health economics, comparative effectiveness research and market access alongside pricing functions.  The added focus to develop a presence in emerging markets creates new pricing challenges, especially when facing an unfamiliar market with unique regulatory and access issues. Continue reading